Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 4/20 | 0.58 |
| ▸ | HTR2A | P28223 | 4/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.57 |
| ▸ | MAPT | P10636 | 1/20 | 0.57 |
| ▸ | RECQL | P46063 | 1/20 | 0.57 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.55 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.52 |
| ▸ | HTR1A | P08908 | 2/20 | 0.51 |
| ▸ | HTR7 | P34969 | 2/20 | 0.51 |
| ▸ | DRD4 | P21917 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30101378 | 1.00 | DRD2 (0.58) | DRD2HTR2AKDM4EALDH1A1MAPT | |
| Hydrochloric Acid SCHEMBL6703246 | 0.98 | DRD2 (0.56) | DRD2HTR2AKDM4EALDH1A1MAPT | |
| SCHEMBL2004470 | 0.94 | DRD2 (0.53) | DRD2HTR2AKDM4EALDH1A1MAPT | |
| SCHEMBL3287137 | 0.85 | KDM4E (0.61) | DRD2HTR2AKDM4EALDH1A1MAPT | |
| SCHEMBL565864 | 0.85 | KDM4E (0.61) | DRD2HTR2AKDM4EALDH1A1MAPT | |
| SCHEMBL15247842 | 0.84 | EPHX2 (0.59) | HTR2AKDM4EALDH1A1RECQLEPHX2 | |
| SCHEMBL6822065 | 0.83 | KDM4E (0.59) | DRD2HTR2AKDM4EALDH1A1MAPT | |
| SCHEMBL30748716 | 0.83 | KDM4E (0.59) | DRD2HTR2AKDM4EALDH1A1MAPT | |
| SCHEMBL3290416 | 0.83 | KDM4E (0.59) | DRD2HTR2AKDM4EALDH1A1MAPT | |
| SCHEMBL2750963 | 0.82 | KDM4E (0.58) | DRD2HTR2AKDM4EALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 236 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2001885-A2 | OCTAHYDRO-PYRROLO[3,4-B]PYRROLE DERIVATIVES | Abbott Laboratories (US) | 2008-12-17 | — | — | EP | claimed |
| WO-2007100990-A2 | OCTAHYDRO-PYRROLO[3,4-B] PYRROLE DERIVATIVES AND THEIR USE AS HISTAMINE-3 RECEPTOR LIGANDS | ABBOTT LABORATORIES (US) | 2007-09-07 | — | — | WO | claimed |
| EP-1432701-A1 | HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF DISORDERS OF THE URINARY TRACT | RECORDATI S.A. CHEMICAL and PHARMACEUTICAL COMPANY (CH) | 2004-06-30 | — | — | EP | claimed |
| WO-2003031436-A1 | HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF DISORDERS OF THE URINARY TRACT | RECORDATI S.A. (CH) | 2003-04-17 | — | — | WO | claimed |
| US-20250214977-A1 | STAT6 INHIBITORS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2025-07-03 | — | — | US | disclosed |
| US-20240166637-A1 | COMPOUNDS AND METHODS FOR TREATING MALARIA | MICROBIOTIX, INC. (US) | 2024-05-23 | — | — | US | disclosed |
| CN-117377665-A | PARP7 inhibitor and application thereof | 北京华森英诺生物科技有限公司 | 2024-01-09 | — | — | CN | disclosed |
| EP-4281077-A1 | COMPOUNDS AND METHODS FOR TREATING MALARIA | Microbiotix, Inc. (US) | 2023-11-29 | — | — | EP | disclosed |
| CN-116916923-A | Compounds and methods for treating malaria | 微生物公司 | 2023-10-20 | — | — | CN | disclosed |
| WO-2023042914-A1 | PYRROLIDINE COMPOUNDS AS HISTONE DEACETYLASE INHIBITORS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2023-03-23 | — | — | WO | disclosed |
| CN-115636787-A | Compound with Tau protein inhibitory activity and preparation method thereof | 北京理工大学 | 2023-01-24 | — | — | CN | disclosed |
| WO-2022159649-A1 | COMPOUNDS AND METHODS FOR TREATING MALARIA | MICROBIOTIX, INC. (US) | 2022-07-28 | — | — | WO | disclosed |
| EP-0288575-A1 | PIPERAZINE COMPOUNDS AND THEIR MEDICINAL USE | Yoshitomi Pharmaceutical Industries, Ltd. (JP) | 1988-11-02 | — | — | EP | disclosed |
| EP-0279598-A2 | Arylpiperazinyl-alkylene-phenyl-heterocyclic compounds | PFIZER INC. (US) | 1988-08-24 | — | — | EP | disclosed |
| EP-0254623-A1 | Aminoalkylthio triazolopyridine or triazoloquinoline derivatives, process for their preparation, medicaments containing them, particularly useful as antalgics | LABORATOIRES UPSA (FR) | 1988-01-27 | — | — | EP | disclosed |
| EP-0200968-A1 | Succinimide derivatives, their production and use | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 1986-11-12 | — | — | EP | disclosed |
| US-4585773-A | DIURETIC, HYPOTENSIVE | BRISTOL-MYERS COMPANY (US) | 1986-04-29 | — | — | US | disclosed |
| US-4456756-A | PSYCHOTHERAPEUTICS | MEAD JOHNSON & COMPANY (US) | 1984-06-26 | — | — | US | disclosed |
| US-4367335-A | PSYCHOLOGICAL DISORDERS | MEAD JOHNSON & COMPANY (US) | 1983-01-04 | — | — | US | disclosed |
| US-4361565-A | PSYCHOTROPIC PROPERTIES | MEAD JOHNSON & COMPANY (US) | 1982-11-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250214977-A1 | STAT6 INHIBITORS AND USES THEREOF | STAT6, STAT5B, STAT5A | DRD2 4747/4885HTR2A 3774/4885KDM4E 444/4885 |
| US-20240166637-A1 | COMPOUNDS AND METHODS FOR TREATING MALARIA | PORCN, VDAC1, VDAC2 | DRD2 4318/4885HTR2A 3639/4885KDM4E 3180/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.